Amgen's Phase 3 trial of bemarituzumab plus chemo met its survival goal in FGFR2b+ gastric cancer, with full data expected ...

Having to take Ozempic or other weight loss drugs can be a real pain in the ass, with users often having to jab themselves ...

Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...

MariTide is designed to combine the effects of glucagon-like peptide-1 (GLP-1) receptor activation with glucose-dependent ...

The once-monthly drug is still under study but could provide added convenience and another option for patients.

Amgen aims to challenge obesity drug leaders with MariTide, a potential monthly treatment now in late-stage trials.

Drugs such as Ozempic (a brand name for semaglutide) are showing promise for weight loss. Another medication in the same ...

Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like ...

Amgen's late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls its ...

At the diabetes conference, Eli Lilly presented results of a phase 1 trial of its experimental drug, eloralintide. Unlike GLP ...

Amgen's weight-loss drug MariTide had a successful Phase 2 trial so the company is expanding development plans to study its use for heart disease and sleep apnea.